CoChat
Sign Up
Cited by 379

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Development and application of hyaluronic acid in tumor targeting drug delivery

Luo, Zhijian, Dai, Yan, Gao, Huile·2019·Acta Pharmaceutica Sinica B
DOI 10.1016/j.apsb.2019.06.004PMC PMC6900560
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.apsb.2019.06.004

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Figures

Graphical abstract Graphical abstract The review summarizes various applications of hyaluronic acid in tumor targeting drug delivery systems based on the specific CD44-targeting capacity and the hyaluronidase degradation property.
Graphical abstract Graphical abstract The review summarizes various applications of hyaluronic acid in tumor targeting drug delivery systems based on the specific CD44-targeting capacity and the hyaluronidase degradation property.CC BY-NC-ND · PubMed Central
Figure 1 In vivo tumor targeting of HA-coated hybrid nanoparticles. Whole body imaging (A), organ imaging (B) and semi-quantitative fluorescent intensity (C) demonstrated the HA coating significantly improved tumor targeting capacity of nanoparticles. Reprinted from Ref. 59 with permission. Copyright © 2018 American Chemical Society.
Figure 1 In vivo tumor targeting of HA-coated hybrid nanoparticles. Whole body imaging (A), organ imaging (B) and semi-quantitative fluorescent intensity (C) demonstrated the HA coating significantly improved tumor targeting capacity of nanoparticles. Reprinted from Ref. 59 with permission. Copyright © 2018 American Chemical Society.CC BY-NC-ND · PubMed Central
Figure 2 Schematic representation of intraperitoneal administration of hyaluronic acid-poly(ethylene imine) (HA-PEI)–microRNA 125b. Reproduced from Ref. 17 with permission. Copyright © 2018 American Chemical Society.
Figure 2 Schematic representation of intraperitoneal administration of hyaluronic acid-poly(ethylene imine) (HA-PEI)–microRNA 125b. Reproduced from Ref. 17 with permission. Copyright © 2018 American Chemical Society.CC BY-NC-ND · PubMed Central
Figure 3 Schematic illustration of the interfering with the lactate-fueled respiration for enhanced photodynamic tumor therapy by a porphyrinic MOF nanoplatform. Reprinted from Ref. 18 with permission. Copyright © 2018 Wiley.
Figure 3 Schematic illustration of the interfering with the lactate-fueled respiration for enhanced photodynamic tumor therapy by a porphyrinic MOF nanoplatform. Reprinted from Ref. 18 with permission. Copyright © 2018 Wiley.CC BY-NC-ND · PubMed Central
Figure 4 (A) Cumulative ICG release and fluorescence recovery with or without hyaluronidase through release procedure. (B) Cellular uptake of nanoparticles after incubation for 4 and 12 h. The white bar represents 50 μm. (C) Cell viability measured by MTT assays. (D) Nanoparticles penetrating into tumor spheroids. The white bar represents 200 μm. (a) represents AuNC@CBSA-ICG, (b) represents AuNC@CBSA-ICG@HA and (c) represents AuNC@CBSA-ICG@HA pretreated with hyaluronidase. (E) The in vitro photothermal effect of formulations measured by Calcein-AM/PI double staining. The white bar represents 200 μm. Reproduced with Ref. 86 with permission of Gao et al.
Figure 4 (A) Cumulative ICG release and fluorescence recovery with or without hyaluronidase through release procedure. (B) Cellular uptake of nanoparticles after incubation for 4 and 12 h. The white bar represents 50 μm. (C) Cell viability measured by MTT assays. (D) Nanoparticles penetrating into tumor spheroids. The white bar represents 200 μm. (a) represents AuNC@CBSA-ICG, (b) represents AuNC@CBSA-ICG@HA and (c) represents AuNC@CBSA-ICG@HA pretreated with hyaluronidase. (E) The in vitro photothermal effect of formulations measured by Calcein-AM/PI double staining. The white bar represents 200 μm. Reproduced with Ref. 86 with permission of Gao et al.CC BY-NC-ND · PubMed Central
Figure 5 (A) Schematic illustration of a cross-linked anionic delivery system, consisting of siRNA-loaded HA-SH/CaP hybrid nanoparticles (NPHA-SH/CaP/siRNA); (B) schematic illustration of tumor-targeted siRNA delivery by HA-SH/CaP nanoparticles. Reproduced with permission from Ref. 105. Copyright © 2017 American Chemical Society.
Figure 5 (A) Schematic illustration of a cross-linked anionic delivery system, consisting of siRNA-loaded HA-SH/CaP hybrid nanoparticles (NPHA-SH/CaP/siRNA); (B) schematic illustration of tumor-targeted siRNA delivery by HA-SH/CaP nanoparticles. Reproduced with permission from Ref. 105. Copyright © 2017 American Chemical Society.CC BY-NC-ND · PubMed Central
Figure 6 The comparison of tumor weight and spleen weight (A and B) at different intervals. Then the survival curve after treatment was recorded (C). ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001. The Dr-AIMS treatment effectively modulated the immunosuppressive TME and further enhanced therapeutic efficacy of immunotherapy. Reprinted from Ref. 25 with permission. Copyright © 2018 Wiley.
Figure 6 The comparison of tumor weight and spleen weight (A and B) at different intervals. Then the survival curve after treatment was recorded (C). ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001. The Dr-AIMS treatment effectively modulated the immunosuppressive TME and further enhanced therapeutic efficacy of immunotherapy. Reprinted from Ref. 25 with permission. Copyright © 2018 Wiley.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 106

  1. Jain, 1988, Mechanisms of heterogeneous distribution of monoclonal antibodies and other macromolecules in tumors: significance of elevated interstitial pressure, Cancer Res, 48, 7022
  2. Fang, 2011, The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect, Adv Drug Deliv Rev, 63, 136, 10.1016/j.addr.2010.04.009 · DOI
  3. Gao, 2016, Progress and perspectives on targeting nanoparticles for brain drug delivery, Acta Pharm Sin B, 6, 268, 10.1016/j.apsb.2016.05.013 · DOI
  4. Sun, 2017, Rational design of cancer nanomedicine: nanoproperty integration and synchronization, Adv Mater, 29, 1606628, 10.1002/adma.201606628 · DOI
  5. Fan, 2017, Nanotechnology for multimodal synergistic cancer therapy, Chem Rev, 117, 13566, 10.1021/acs.chemrev.7b00258 · DOI
  6. Shi, 2017, Cancer nanomedicine: progress, challenges and opportunities, Nat Rev Canc, 17, 20, 10.1038/nrc.2016.108 · DOI · Paper page
  7. Weissig, 2014, Nanopharmaceuticals (part 1): products on the market, Int J Nanomed, 9, 4357, 10.2147/IJN.S46900 · DOI
  8. Weissig, 2015, Nanopharmaceuticals (part 2): products in the pipeline, Int J Nanomed, 10, 1245, 10.2147/IJN.S65526 · DOI
  9. Wickens, 2017, Recent advances in hyaluronic acid-decorated nanocarriers for targeted cancer therapy, Drug Discov Today, 22, 665, 10.1016/j.drudis.2016.12.009 · DOI
  10. Schaefer, 2010, Proteoglycans: from structural compounds to signaling molecules, Cell Tissue Res, 339, 237, 10.1007/s00441-009-0821-y · DOI
  11. Underhill, 1992, CD44: the hyaluronan receptor, J Cell Sci, 103, 293, 10.1242/jcs.103.2.293 · DOI
  12. Swierczewska, 2016, Polysaccharide-based nanoparticles for theranostic nanomedicine, Adv Drug Deliv Rev, 99, 70, 10.1016/j.addr.2015.11.015 · DOI
  13. Kim, 2017, Hyaluronate and its derivatives for customized biomedical applications, Biomaterials, 123, 155, 10.1016/j.biomaterials.2017.01.029 · DOI
  14. Dosio, 2016, Hyaluronic acid for anticancer drug and nucleic acid delivery, Adv Drug Deliv Rev, 97, 204, 10.1016/j.addr.2015.11.011 · DOI
  15. Seok, 2018, CD44 targeting biocompatible and biodegradable hyaluronic acid cross-linked zein nanogels for curcumin delivery to cancer cells: in vitro and in vivo evaluation, J Control Release, 280, 20, 10.1016/j.jconrel.2018.04.050 · DOI
  16. Mine, 2003, Hepatocyte growth factor enhances adhesion of breast cancer cells to endothelial cells in vitro through up-regulation of CD44, Exp Cell Res, 288, 189, 10.1016/S0014-4827(03)00184-8 · DOI
  17. Parayath, 2018, Repolarization of Tumor-associated macrophages in a genetically engineered nonsmall cell lung cancer model by intraperitoneal administration of hyaluronic acid-based nanoparticles encapsulating microRNA-125b, Nano Lett, 18, 3571, 10.1021/acs.nanolett.8b00689 · DOI
  18. Chen, 2018, Interfering with lactate-fueled respiration for enhanced photodynamic tumor therapy by a porphyrinic MOF nanoplatform, Adv Funct Mater, 28, 1803498, 10.1002/adfm.201803498 · DOI
  19. Gotov, 2018, Docetaxel-loaded hyaluronic acid–cathepsin B-cleavable-peptide-gold nanoparticles for the treatment of cancer, Mol Pharm, 15, 4668, 10.1021/acs.molpharmaceut.8b00640 · DOI
  20. Zhang, 2016, A hyaluronidase-responsive nanoparticle-based drug delivery system for targeting colon cancer cells, Cancer Res, 76, 7208, 10.1158/0008-5472.CAN-16-1681 · DOI
  21. Zhang, 2014, Activatable hyaluronic acid nanoparticle as a theranostic agent for optical/photoacoustic image-guided photothermal therapy, ACS Nano, 8, 12250, 10.1021/nn506130t · DOI
  22. Miyazaki, 2018, Hyaluronic acid-based pH-sensitive polymer-modified liposomes for cell-specific intracellular drug delivery systems, Bioconjug Chem, 29, 44, 10.1021/acs.bioconjchem.7b00551 · DOI
  23. Yin, 2017, Redox sensitive hyaluronic acid-decorated graphene oxide for photothermally controlled tumor-cytoplasm-selective rapid drug delivery, Adv Funct Mater, 27, 1604620, 10.1002/adfm.201604620 · DOI
  24. Ren, 2018, Degradation-regulatable architectured implantable macroporous scaffold for the spatiotemporal modulation of immunosuppressive microenvironment and enhanced combination cancer immunotherapy, Adv Funct Mater, 28, 1804490, 10.1002/adfm.201804490 · DOI
  25. Suh, 2004, Soft lithographic patterning of hyaluronic acid on hydrophilic substrates using molding and printing, Adv Mater, 16, 584, 10.1002/adma.200306180 · DOI
  26. Gao, 2014, The interaction of nanoparticles with plasma proteins and the consequent influence on nanoparticles behavior, Expert Opin Drug Deliv, 11, 409, 10.1517/17425247.2014.877442 · DOI
  27. Nel, 2009, Understanding biophysicochemical interactions at the nano-bio interface, Nat Mater, 8, 543, 10.1038/nmat2442 · DOI · Paper page
  28. Xiao, 2018, Influence of ligands property and particle size of gold nanoparticles on the protein adsorption and corresponding targeting ability, Int J Pharm, 538, 105, 10.1016/j.ijpharm.2018.01.011 · DOI
  29. Zhang, 2018, Ligand size and conformation affect the behavior of nanoparticles coated with in vitro and in vivo protein corona, ACS Appl Mater Interfaces, 10, 9094, 10.1021/acsami.7b16096 · DOI
  30. Aggarwal, 2009, Nanoparticle interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic efficacy, Adv Drug Deliv Rev, 61, 428, 10.1016/j.addr.2009.03.009 · DOI · Paper page
  31. Kolate, 2014, PEG—a versatile conjugating ligand for drugs and drug delivery systems, J Control Release, 192C, 67, 10.1016/j.jconrel.2014.06.046 · DOI
  32. Almalik, 2017, Hyaluronic acid coated chitosan nanoparticles reduced the immunogenicity of the formed protein corona, Sci Rep, 7, 10542, 10.1038/s41598-017-10836-7 · DOI
  33. Stern, 2006, Hyaluronidases: their genomics, structures, and mechanisms of action, Chem Rev, 106, 818, 10.1021/cr050247k · DOI
  34. Itano, 2008, Altered hyaluronan biosynthesis in cancer progression, Semin Canc Biol, 18, 268, 10.1016/j.semcancer.2008.03.006 · DOI
  35. Misra, 2011, Hyaluronan–CD44 interactions as potential targets for cancer therapy, FEBS J, 278, 1429, 10.1111/j.1742-4658.2011.08071.x · DOI · Paper page
  36. Wu, 2015, A novel role of low molecular weight hyaluronan in breast cancer metastasis, FASEB J, 29, 1290, 10.1096/fj.14-259978 · DOI
  37. Gunthert, 1991, A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells, Cell, 65, 13, 10.1016/0092-8674(91)90403-L · DOI
  38. Zoller, 2011, CD44: can a cancer-initiating cell profit from an abundantly expressed molecule?. llular matrix receptor functions affect tumor susceptibility and progres, Nat Rev Canc, 11, 254, 10.1038/nrc3023 · DOI
  39. Jaggupilli, 2012, Significance of CD44 and CD24 as cancer stem cell markers: an enduring ambiguity, Clin Dev Immunol, 2012, 708036, 10.1155/2012/708036 · DOI
  40. Su, 2011, Identification of cancer stem-like CD44+ cells in human nasopharyngeal carcinoma cell line, Arch Med Res, 42, 15, 10.1016/j.arcmed.2011.01.007 · DOI
  41. Leung, 2010, Non-small cell lung cancer cells expressing CD44 are enriched for stem cell-like properties, PLoS One, 5, e14062, 10.1371/journal.pone.0014062 · DOI
  42. Okada, 2010, MicroRNAs in immune regulation—opportunities for cancer immunotherapy, Int J Biochem Cell Biol, 42, 1256, 10.1016/j.biocel.2010.02.002 · DOI
  43. He, 2018, A multi-functional macrophage and tumor targeting gene delivery system for the regulation of macrophage polarity and reversal of cancer immunoresistance, Nanoscale, 10, 15578, 10.1039/C8NR05294H · DOI
  44. Telmer, 2011, How does a protein with dual mitotic spindle and extracellular matrix receptor functions affect tumor susceptibility and progression?., Commun Integr Biol, 4, 182, 10.4161/cib.4.2.14270 · DOI
  45. Gust, 2009, RHAMM (CD168) is overexpressed at the protein level and may constitute an immunogenic antigen in advanced prostate cancer disease, Neoplasia, 11, 956, 10.1593/neo.09694 · DOI
  46. Shigeishi, 2009, Overexpression of the receptor for hyaluronan-mediated motility, correlates with expression of microtubule-associated protein in human oral squamous cell carcinomas, Int J Oncol, 34, 1565, 10.3892/ijo_00000286 · DOI
  47. Pandey, 2014, J Biol Chem, 289, 21807, 10.1074/jbc.M114.565846 · DOI
  48. Pandey, 2013, The hyaluronan receptor for endocytosis (HARE) activates NF-kappaB-mediated gene expression in response to 40–400-kDa, but not smaller or larger, hyaluronans, J Biol Chem, 288, 14068, 10.1074/jbc.M112.442889 · DOI
  49. Girish, 2007, The magic glue hyaluronan and its eraser hyaluronidase: a biological overview, Life Sci, 80, 1921, 10.1016/j.lfs.2007.02.037 · DOI
  50. Bertrand, 1997, Increased hyaluronidase levels in breast tumor metastases, Int J Cancer, 73, 327, 10.1002/(SICI)1097-0215(19971104)73:3<327::AID-IJC4>3.0.CO;2-1 · DOI
  51. Lokeshwar, 2001, Stromal and epithelial expression of tumor markers hyaluronic acid and HYAL1 hyaluronidase in prostate cancer, J Biol Chem, 276, 11922, 10.1074/jbc.M008432200 · DOI
  52. Delpech, 2002, Hyaluronidase is more elevated in human brain metastases than in primary brain tumours, Anticancer Res, 22, 2423
  53. Tan, 2011, HYAL1 overexpression is correlated with the malignant behavior of human breast cancer, Int J Cancer, 128, 1303, 10.1002/ijc.25460 · DOI
  54. De Stefano, 2011, Hyaluronic acid–paclitaxel: effects of intraperitoneal administration against CD44+ human ovarian cancer xenografts, Cancer Chemother Pharmacol, 68, 107, 10.1007/s00280-010-1462-2 · DOI
  55. Banzato, 2009, Biodistribution imaging of a paclitaxel–hyaluronan bioconjugate, Nucl Med Biol, 36, 525, 10.1016/j.nucmedbio.2009.02.005 · DOI
  56. Vogus, 2017, A hyaluronic acid conjugate engineered to synergistically and sequentially deliver gemcitabine and doxorubicin to treat triple negative breast cancer, J Control Release, 267, 191, 10.1016/j.jconrel.2017.08.016 · DOI
  57. Zhang, 2018, A versatile prodrug strategy to in situ encapsulate drugs in MOF nanocarriers: a case of cytarabine-IR820 prodrug encapsulated ZIF-8 toward chemo-photothermal therapy, Adv Funct Mater, 28, 1802830, 10.1002/adfm.201802830 · DOI
  58. Wang, 2018, Combination-responsive MoO3-x-hybridized hyaluronic acid hollow nanospheres for cancer phototheranostics, ACS Appl Mater Interfaces, 10, 42088, 10.1021/acsami.8b15818 · DOI
  59. Wang, 2017, A triple-synergistic strategy for combinational photo/radiotherapy and multi-modality imaging based on hyaluronic acid-hybridized polyaniline-coated WS2 nanodots, Nanoscale, 9, 5551, 10.1039/C6NR09219E · DOI
  60. Shen, 2015, Coating solid lipid nanoparticles with hyaluronic acid enhances antitumor activity against melanoma stem-like cells, Theranostics, 5, 755, 10.7150/thno.10804 · DOI
  61. Marengo, 2019, Pancreatic cancer stem cell proliferation is strongly inhibited by diethyldithiocarbamate–copper complex loaded into hyaluronic acid decorated liposomes, Biochim Biophys Acta Gen Subj, 1863, 61, 10.1016/j.bbagen.2018.09.018 · DOI
  62. An, 2017, Regulation of multidrug resistance by microRNAs in anti-cancer therapy, Acta Pharm Sin B, 7, 38, 10.1016/j.apsb.2016.09.002 · DOI
  63. Gaio, 2018, Co-delivery of docetaxel and disulfonate tetraphenyl chlorin in one nanoparticle produces strong synergism between chemo- and photodynamic therapy in drug-sensitive and -resistant cancer cells, Mol Pharm, 15, 4599, 10.1021/acs.molpharmaceut.8b00597 · DOI
  64. Dintaman, 1999, Inhibition of P-glycoprotein by d-alpha-tocopheryl polyethylene glycol 1000 succinate (TPGS), Pharm Res (N Y), 16, 1550, 10.1023/A:1015000503629 · DOI
  65. Zhang, 2018, CD44-targeted facile enzymatic activatable chitosan nanoparticles for efficient antitumor therapy and reversal of multidrug resistance, Biomacromolecules, 19, 883, 10.1021/acs.biomac.7b01676 · DOI
  66. Li, 2019, Redox-responsive hyaluronic acid nanogels for hyperthermia-assisted chemotherapy to overcome multidrug resistance, Carbohydr Polym, 203, 378, 10.1016/j.carbpol.2018.09.076 · DOI
  67. Perez-Escuredo, 2016, Monocarboxylate transporters in the brain and in cancer, Biochim Biophys Acta, 1863, 2481, 10.1016/j.bbamcr.2016.03.013 · DOI
  68. Sonveaux, 2008, Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice, J Clin Investig, 118, 3930
  69. Chen, 2014, A multi-synergistic platform for sequential irradiation-activated high-performance apoptotic cancer therapy, Adv Funct Mater, 24, 522, 10.1002/adfm.201301951 · DOI
  70. He, 2018, Effective and selective anti-cancer protein delivery via all-functions-in-one nanocarriers coupled with visible light-responsive, reversible protein engineering, Adv Funct Mater, 28, 1706710, 10.1002/adfm.201706710 · DOI
  71. Cun, 2016, A dual strategy to improve the penetration and treatment of breast cancer by combining shrinking nanoparticles with collagen depletion by losartan, Acta Biomater, 31, 186, 10.1016/j.actbio.2015.12.002 · DOI
  72. Decuzzi, 2010, Size and shape effects in the biodistribution of intravascularly injected particles, J Control Release, 141, 320, 10.1016/j.jconrel.2009.10.014 · DOI
  73. Tang, 2014, Investigating the optimal size of anticancer nanomedicine, Proc Natl Acad Sci U S A, 111, 15344, 10.1073/pnas.1411499111 · DOI
  74. Kibria, 2013, The effect of liposomal size on the targeted delivery of doxorubicin to integrin alphavbeta3-expressing tumor endothelial cells, Biomaterials, 34, 5617, 10.1016/j.biomaterials.2013.03.094 · DOI
  75. Hickey, 2015, Control of polymeric nanoparticle size to improve therapeutic delivery, J Control Release, 219, 536, 10.1016/j.jconrel.2015.10.006 · DOI
  76. Ruan, 2016, Increased gold nanoparticle retention in brain tumors by in situ enzyme-induced aggregation, ACS Nano, 10, 10086, 10.1021/acsnano.6b05070 · DOI
  77. Shen, 2017, Spatial targeting of tumor-associated macrophages and tumor cells with a pH-sensitive cluster nanocarrier for cancer chemoimmunotherapy, Nano Lett, 17, 3822, 10.1021/acs.nanolett.7b01193 · DOI
  78. Wei, 2018, High-efficient clearable nanoparticles for multi-modal imaging and image-guided cancer therapy, Adv Funct Mater, 28, 1704634, 10.1002/adfm.201704634 · DOI
  79. Ruan, 2015, Matrix metalloproteinase-sensitive size-shrinkable nanoparticles for deep tumor penetration and pH triggered doxorubicin release, Biomaterials, 60, 100, 10.1016/j.biomaterials.2015.05.006 · DOI
  80. Li, 2016, Hyaluronic acid ion-pairing nanoparticles for targeted tumor therapy, J Control Release, 225, 170, 10.1016/j.jconrel.2016.01.049 · DOI
  81. Cadete, 2016, Targeting cancer with hyaluronic acid-based nanocarriers: recent advances and translational perspectives, Nanomedicine, 11, 2341, 10.2217/nnm-2016-0117 · DOI
  82. Liu, 2019, Theranostic nanoparticles with tumor-specific enzyme-triggered size reduction and drug release to perform photothermal therapy for breast cancer treatment, Acta Pharm Sin B, 9, 410, 10.1016/j.apsb.2018.09.001 · DOI
  83. Qin, 2018, The application of nitric oxide delivery in nanoparticle-based tumor targeting drug delivery and treatment, Asian J Pharm Sci, 14, 66
  84. Hu, 2018, Enzyme-triggered size shrink and laser-enhanced NO release nanoparticles for deep tumor penetration and combination therapy, Biomaterials, 168, 64, 10.1016/j.biomaterials.2018.03.046 · DOI
  85. Hu, 2018, Coadministration of iRGD with multistage responsive nanoparticles enhanced tumor targeting and penetration abilities for breast cancer therapy, ACS Appl Mater Interfaces, 10, 22571, 10.1021/acsami.8b04847 · DOI
  86. Cun, 2015, A novel strategy through combining iRGD peptide with tumor-microenvironment-responsive and multistage nanoparticles for deep tumor penetration, ACS Appl Mater Interfaces, 7, 27458, 10.1021/acsami.5b09391 · DOI
  87. Ruan, 2017, Ligand-mediated and enzyme-directed precise targeting and retention for the enhanced treatment of glioblastoma, ACS Appl Mater Interfaces, 9, 20348, 10.1021/acsami.7b02303 · DOI
  88. Ruan, 2015, Matrix metalloproteinase triggered size-shrinkable gelatin–gold fabricated nanoparticles for tumor microenvironment sensitive penetration and diagnosis of glioma, Nanoscale, 7, 9487, 10.1039/C5NR01408E · DOI
  89. Han, 2017, MMP-2-sensitive HA end-conjugated poly(amidoamine) dendrimers via click reaction to enhance drug penetration into solid tumor, ACS Appl Mater Interfaces, 9, 42459, 10.1021/acsami.7b10098 · DOI
  90. Han, 2016, Gold-nanoclustered hyaluronan nano-assemblies for photothermally maneuvered photodynamic tumor ablation, ACS Nano, 10, 10858, 10.1021/acsnano.6b05113 · DOI
  91. Ruan, 2015, Tumor microenvironment sensitive doxorubicin delivery and release to glioma using angiopep-2 decorated gold nanoparticles, Biomaterials, 37, 425, 10.1016/j.biomaterials.2014.10.007 · DOI
  92. Lee, 2008, Recent progress in tumor pH targeting nanotechnology, J Control Release, 132, 164, 10.1016/j.jconrel.2008.05.003 · DOI
  93. Ding, 2018, PH-sensitive coiled-coil peptide-cross-linked hyaluronic acid nanogels: synthesis and targeted intracellular protein delivery to CD44 positive cancer cells, Biomacromolecules, 19, 555, 10.1021/acs.biomac.7b01664 · DOI
  94. Du, 2018, Reduction-sensitive mixed micelles for selective intracellular drug delivery to tumor cells and reversal of multidrug resistance, Int J Pharm, 550, 1, 10.1016/j.ijpharm.2018.08.019 · DOI
  95. Cai, 2017, Reduction- and pH-sensitive hyaluronan nanoparticles for delivery of iridium (III) anticancer drugs, Biomacromolecules, 18, 2102, 10.1021/acs.biomac.7b00445 · DOI
  96. Debele, 2018, PH- and GSH-sensitive hyaluronic acid–MP conjugate micelles for intracellular delivery of doxorubicin to colon cancer cells and cancer stem cells, Biomacromolecules, 19, 3725, 10.1021/acs.biomac.8b00856 · DOI
  97. Song, 2018, Paclitaxel-loaded redox-sensitive nanoparticles based on hyaluronic acid–vitamin E succinate conjugates for improved lung cancer treatment, Int J Nanomed, 13, 1585, 10.2147/IJN.S155383 · DOI
  98. Tian, 2018, Tween 80-modified hyaluronic acid-ss-curcumin micelles for targeting glioma: synthesis, characterization and their in vitro evaluation, Int J Biol Macromol, 120, 2579, 10.1016/j.ijbiomac.2018.09.034 · DOI
  99. Zhou, 2017, Bioreducible cross-linked hyaluronic acid/calcium phosphate hybrid nanoparticles for specific delivery of siRNA in melanoma tumor therapy, ACS Appl Mater Interfaces, 9, 14576, 10.1021/acsami.6b15347 · DOI
  100. Gu, 2018, Hyaluronic acid shell and disulfide-crosslinked core micelles for in vivo targeted delivery of bortezomib for the treatment of multiple myeloma, Acta Biomater, 80, 288, 10.1016/j.actbio.2018.09.022 · DOI
  101. Yin, 2018, Free adriamycin-loaded pH/reduction dual-responsive hyaluronic acid–adriamycin prodrug micelles for efficient cancer therapy, ACS Appl Mater Interfaces, 10, 35693, 10.1021/acsami.8b09342 · DOI
  102. Lin, 2017, pH and redox dual stimulate-responsive nanocarriers based on hyaluronic acid coated mesoporous silica for targeted drug delivery, Mater Sci Eng C Mater Biol Appl, 81, 478, 10.1016/j.msec.2017.08.036 · DOI
  103. Burdick, 2011, Hyaluronic acid hydrogels for biomedical applications, Adv Mater, 23, H41, 10.1002/adma.201003963 · DOI
  104. Yang, 2015, Hyaluronic acid nanogels with enzyme-sensitive cross-linking group for drug delivery, J Control Release, 205, 206, 10.1016/j.jconrel.2015.02.008 · DOI
  105. Verbeke, 2015, Injectable, pore-forming hydrogels for in vivo enrichment of immature dendritic cells, Adv Healthc Mater, 4, 2677, 10.1002/adhm.201500618 · DOI
  106. Xiao, 2018, The impact of protein corona on the behavior and targeting capability of nanoparticle-based delivery system, Int J Pharm, 552, 328, 10.1016/j.ijpharm.2018.10.011 · DOI

Cited by

Sorted by citations

See all 379

Metadata

Authors
Luo, Z., Dai, Y., & Gao, H.
Venue
Acta Pharmaceutica Sinica B
Publisher
Elsevier BV
Published
2019-11
Volume
9
Issue
6
Pages
1099-1112
ISSN
2211-3835
DOI
10.1016/j.apsb.2019.06.004
PMC
PMC6900560
Cited by
379
References
5
Language
en
Licence
Funders
  • National Natural Science Foundation of China (31571016, 81872806)
  • China Academy of Space Technology (2017QNRC001)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review